Table 2 Incidence of Drug-related Adverse Event by COSTART terma
Blinded Period | Open-Label Period | Follow-Up Period | ||
|---|---|---|---|---|
Fenoldopam | Fenoldopam | |||
0.05 | 3.2 | Fenoldopam | Fenoldopam[PR2] | |
Adverse | mcg/kg/min | mcg/kg/min | [PR1](N = 74) | (N = 77[PR3]) |
Events | (N = 15) | (N = 15) | ||
OVERALL | 1 (7%) | 3 (20%) | 13 (17%) | 1 (1%) |
Hypotension | 1 (7%) | 3 (20%) | 9 (12%) | 0 |
Tachycardia | 0 | 0 | 2 (3%) | 0 |
Bradycardia | 0 | 0 | 1 (1%) | 0 |
Hemorrhage | 0 | 0 | 1 (1%) | 0 |
Hypokalemia | 0 | 0 | 1 (1%) | 0 |
Oliguria | 0 | 0 | 0 | 1 (1%) |